… 17: The Saudi Food and Drug Authority (SFDA) has granted conditional … subcutaneous injection, while for bladder cancer unresponsive to standard treatments, it is delivered … for patients with limited treatment options. In NSCLC, trials involving patients whose …

A mum-of-two from Kirkby Lonsdale has become the first patient in the region to receive innovative treatment for bladder cancer. Rosemere Cancer Foundation has funded the launch of the treatment, making Lancashire and south Cumbria’s regional specialist …

… a history of ESRD, bladder cancer, supraventricular tachycardia, and thrombosis … third day of antibacterial drug treatment, the NLR value … to individualized pharmaceutical care from clinical pharmacists and the … patients. Kor J Intern Med. 2015;30(2):198 …

ImmunityBio, Inc. (NASDAQ:IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue. IBRX Reports 700% Revenue Surge in 2025 ImmunityBio announced …

… line mCRC. Instead, earlier treatment settings and expansions into … group of muscle-invasive bladder cancer patients into a phase … first Merck-sponsored pivotal trial under the collaboration, kicked … to work with Big Pharma through Cabometyx, which Morrissey …

… randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC … U.S. Food and Drug Administration (FDA) by the end … despite receiving no additional treatment after the initial eight doses … date with no further treatment after a total of …

… with muscle-invasive bladder cancer Astellas Pharma Co. Ltd … 4 directed antibody-drug conjugate, in … bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial … treatment journey for patients with muscle-invasive bladder cancer …

… treatment for patients with BCG-unresponsive non–muscle-invasive bladder cancer … ;3 QUILT-3.032 trial (NCT03022825) supported the … the kind of innovative treatments ImmunityBio is developing,” Adcock … of 2026. Saudi FDA grants accelerated approval to …

… and consumer-facing websites for bladder cancer drug Anktiva. Both pages include … According to the FDA, however, the trial referenced by the … statement sent to Fierce Pharma Marketing. "We … lacking clarity about his treatment path. Brukinsa offers that …

… United States. Anktiva is a treatment developed by Soon-Shiong’s … by the FDA to treat a specific type of bladder cancer, despite Soon … now really significant proof, multiple trials, 10 years of work in … -funded the development of the drug. “The money spent to …